Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Cirmtuzumab Plus Ibrutinib Shows Activity and Tolerability in MCL and CLL

June 16th 2020

Hun Ju Lee, MD, discusses the interim results of a study examining cirmtuzumab plus ibrutinib and the next steps with this research in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Maintenance Rituximab Improves Survival in Older Patients With MCL, But More Work Needed

June 16th 2020

Reem Karmali, MD, discusses survival outcomes in older patients with MCL with maintenance rituximab and highlights other ongoing MCL research efforts to optimize maintenance strategies in this patient population.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Karmali on the Importance of Evaluating Older Patients With MCL in the Rituximab Era

June 10th 2020

Reem Karmali, MD, MS, discusses the importance of evaluating older patients with mantle cell lymphoma in the rituximab era.

Dr. Wang on the Impact of KTE-X19 on Outcomes in Higher- Versus Lower-Risk MCL

June 10th 2020

Michael Wang, MD, discusses the safety and effectiveness of the autologous anti-CD19 CAR T-cell therapy KTE-X19 in patients with higher- versus lower-risk mantle cell lymphoma.

Dr. Ruan on Stratifying Risk in MCL

June 9th 2020

Jia Ruan, MD, PhD, discusses stratifying risk in mantle cell lymphoma.

Dr. Karmali on Limitations of Intensive Therapy in Older/Medically Unfit Patients With MCL

June 6th 2020

Reem Karmali, MD, MS, discusses the limitations of intensive therapy in older and medically unfit patients with mantle cell lymphoma (MCL).

Zanubrutinib Gains Approval in China for Relapsed/Refractory CLL/SLL and MCL

June 3rd 2020

China's National Medical Products Administration has approved zanubrutinib (Brukinsa) for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma who have received at least 1 prior therapy, as well as for the treatment of adult patients with mantle cell lymphoma who have received at least 1 prior therapy.

Dr. Lee on Cirmtuzumab/Ibrutinib Dosing in MCL and CLL

June 3rd 2020

Hun Ju Lee, MD, discusses dosing of the combination of the investigational ROR1 inhibitor cirmtuzumab and ibrutinib in mantle cell lymphoma and chronic lymphocytic leukemia.

MCL Paradigm Moves Toward More Nuanced Risk Stratification, Novel Treatments

June 2nd 2020

Jia Ruan, MD, PhD, discusses the current risk-stratification parameters and the evolution of treatment from high-intensity chemoimmunotherapy to novel therapy in mantle cell lymphoma.

Dr. Wang on Correlative Data From the ZUMA-2 Trial in MCL

June 2nd 2020

Michael Wang, MD, discusses correlative data from the phase 2 ZUMA-2 trial in mantle cell lymphoma (MCL).

KTE-X19 Demonstrates Comparable Pharmacologic, Clinical Outcomes to Approved Therapies in MCL

May 30th 2020

The pharmacodynamic profile of KTE-X19, an autologous anti-CD19 CAR T-cell therapy, was associated with efficacy and treatment-related neurological events among patients with relapsed/refractory mantle cell lymphoma treated within the ZUMA-2 trial.

Dr. Jain on Next Steps for Venetoclax in Relapsed MCL

May 22nd 2020

Preetesh Jain, MD, PhD, discusses the next steps for a study examining the efficacy of venetoclax in high risk relapsed mantle cell lymphoma.

Dr. Miklos on Development Process for KTE-X19 in MCL

May 20th 2020

David Miklos, MD, discusses the process of developing KTE-X19 and the ZUMA-2 trial in mantle cell lymphoma.

Dr. Jain on Response and Resistance to Venetoclax in Relapsed/Refractory MCL

May 20th 2020

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Venetoclax Shows Marked Responses and Distinct Resistance Mechanisms in MCL

May 19th 2020

Preetesh Jain, MD, PhD, evaluates mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Venetoclax Shows Marked Responses and Distinct Resistance Mechanisms in MCL

May 19th 2020

Preetesh Jain, MD, PhD, evaluated mechanisms of resistance to venetoclax in patients with heavily pretreated mantle cell lymphoma and the next phase of this research.

Dr. Smith on Ongoing Research in Relapsed/Refractory MCL

May 18th 2020

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Precision Medicine: The Next Paradigm Shift in MCL

May 17th 2020

Michael Wang, MD, discusses paradigm shifts in lymphomas and the research efforts driving precision medicine in mantle cell lymphoma.

Dr. Wang on Research Trends in MCL

May 16th 2020

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).